AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers correlated with diastolic dysfunction (E/e')
Number of subjects: 86
Study 28100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers correlated with left atrial volume index
Number of subjects: 86
Study 28101105 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Administration of nan
Number of subjects: 0
Study 28101354 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin/S-1 (GCS) combination therapy intravenously at doses of 1,000 mg/m² or 25 mg/m²
Number of subjects: 1
Study 28101959 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal algorithm for rejection versus all nonrejection
Number of subjects: 703
Study 28101959 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective algorithm for ABMR or TCMR
Number of subjects: 703
Study 28101959 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct comparison of ABMR versus TCMR
Number of subjects: 703
Study 28101959 — intervention group
Group type: EXPERIMENTAL
Intervention: Union of top 200 transcripts from universal and selective algorithms
Number of subjects: 703
Study 28103201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha therapy (Adalimumab, Infliximab, Etanercept)
Number of subjects: 38
Study 28103201 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF alpha therapy (Adalimumab, Infliximab)
Number of subjects: 38
Study 28103201 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anti-TNF alpha therapy)
Number of subjects: 38
Study 28103715 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28103725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib followed by romidepsin on days 1, 8, and 15
Number of subjects: 18
Study 28103831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for nAMD
Number of subjects: 5150
Study 28103831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for DME
Number of subjects: 5150
Study 28103831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for BRVO
Number of subjects: 5150
Study 28103831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment for CRVO
Number of subjects: 5150
Study 28103831 — intervention group
Group type: EXPERIMENTAL
Intervention: NIS OCEAN
Number of subjects: 5150
Study 28103853 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Therapy
Number of subjects: 40
Study 28103853 — intervention group
Group type: COMPARATOR
Intervention: Land-based Therapy
Number of subjects: 40
Study 28103875 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum infection (all infections)
Number of subjects: 396
Study 28103875 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum infection (sub-microscopic infections)
Number of subjects: 396
Study 28103875 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-microscopic P. falciparum infections
Number of subjects: 396
Study 28103875 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased UA resistance index
Number of subjects: 396
Study 28103875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cerebroplacental Doppler ratio
Number of subjects: 396
Study 28103898 — intervention group
Group type: EXPERIMENTAL
Intervention: AL amyloidosis patients (n=341)
Number of subjects: 341
Study 28103898 — intervention group
Group type: EXPERIMENTAL
Intervention: AL amyloidosis patients with recently diagnosed disease and cardiac involvement
Number of subjects: 341
Study 28104185 — intervention group
Group type: EXPERIMENTAL
Intervention: Causative pathogens identified in patients with sepsis
Number of subjects: 1578
Study 28104185 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day mortality in children
Number of subjects: 1578
Study 28104185 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-day mortality in adults
Number of subjects: 1578
Study 28104185 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis on enrolment in children
Number of subjects: 1578
Study 28104185 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe sepsis on enrolment in adults
Number of subjects: 1578
Study 28104185 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of severe sepsis with mortality
Number of subjects: 1578
Study 28104208 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free drug-filled stent (DFS)
Number of subjects: 100
Study 28104208 — intervention group
Group type: COMPARATOR
Intervention: Resolute zotarolimus-eluting stent (historical control)
Number of subjects: 100
Study 28104211 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon post-dilation (BPD)
Number of subjects: 3532
Study 28104211 — intervention group
Group type: COMPARATOR
Intervention: No balloon post-dilation (Control)
Number of subjects: 3532
Study 28104702 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 treatment
Number of subjects: 100
Study 28104702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IL-2 treatment)
Number of subjects: 100
Study 28105667 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective upper airway stimulation (sUAS)
Number of subjects: 20
Study 28106016 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 6264
Study 28106016 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy in low-risk patients
Number of subjects: 6264
Study 28106016 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy in high-risk patients
Number of subjects: 6264
Study 28106016 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 6264
Study 28106016 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-BLED score
Number of subjects: 6264
Study 28106655 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral polyacrylamide hydrogel injection
Number of subjects: 81
Study 28107221 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + cash
Number of subjects: 805
Study 28107221 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + food
Number of subjects: 805
Study 28107221 — intervention group
Group type: COMPARATOR
Intervention: NAC-only
Number of subjects: 805
Study 28107221 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC + cash vs NAC + food
Number of subjects: 805
Study 28107350 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional deliveries attended by skilled birth attendants
Number of subjects: 5469
Study 28107350 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mortality ratio
Number of subjects: 5469
Study 28107350 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal mortality ratio
Number of subjects: 5469
Study 28107350 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal mortality ratio
Number of subjects: 5469
Study 28107350 — intervention group
Group type: EXPERIMENTAL
Intervention: Stillbirth rate
Number of subjects: 5469
Study 28108386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy and Amitriptyline (CBT+A)
Number of subjects: 135
Study 28108386 — intervention group
Group type: COMPARATOR
Intervention: Headache Education and Amitriptyline (HE+A)
Number of subjects: 135
Study 28108768 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypercapnia developing within the first 48 hours after the start of mechanical ventilation
Number of subjects: 1899
Study 28108768 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 1899
Study 28109243 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal hyperbilirubinemia treatment
Number of subjects: 0
Study 28109243 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with neonatal hyperbilirubinemia
Number of subjects: 0
Study 28109243 — intervention group
Group type: COMPARATOR
Intervention: Infants without neonatal hyperbilirubinemia
Number of subjects: 0
Study 28109259 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-pressure lowering agents and statins
Number of subjects: 1127
Study 28109259 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 1127
Study 28109276 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsystem model of care implementation
Number of subjects: 0
Study 28109276 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsystem model of care
Number of subjects: 0
Study 28109571 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented gender-mismatched -80°C cryopreserved aortic allograft for airway reconstruction
Number of subjects: 2
Study 28109895 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound-guided HIFU treatment using volumetric shell ablation technique
Number of subjects: 73
Study 28109895 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound-guided HIFU treatment
Number of subjects: 73
Study 28109951 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia informed consent video and website incorporating cognitive strategies (15-min duration)
Number of subjects: 0
Study 28109951 — intervention group
Group type: COMPARATOR
Intervention: Conventional informed consent process
Number of subjects: 0
Study 28110120 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 0
Study 28110120 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate dialysis (BHD)
Number of subjects: 0
Study 28110346 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative imaging and molecular biomarkers
Number of subjects: 109
Study 28110770 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 118
Study 28110770 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 118
Study 28110982 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-MRI
Number of subjects: 576
Study 28110982 — intervention group
Group type: COMPARATOR
Intervention: TRUS-biopsy
Number of subjects: 576
Study 28111758 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of 120 mmHg (intensive)
Number of subjects: 0
Study 28111758 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure target of 140 mmHg (standard)
Number of subjects: 0
Study 28111925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab, irinotecan, and temozolomide (BIT)
Number of subjects: 33
Study 28112798 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary perioperative protocol
Number of subjects: 600
Study 28112798 — intervention group
Group type: COMPARATOR
Intervention: Control (historical cohort)
Number of subjects: 600
Study 28113028 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28114316 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal conditional weight gain (CWG) in the first window (≤ 20 weeks)
Number of subjects: 1436
Study 28114316 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal conditional weight gain (CWG) in the second window (21-29 weeks)
Number of subjects: 1436
Study 28114316 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal conditional weight gain (CWG) in the third window (≥ 30 weeks)
Number of subjects: 1436
Study 28114316 — intervention group
Group type: COMPARATOR
Intervention: Women gaining below the Institute of Medicine guidelines
Number of subjects: 1436
Study 28114441 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk group (41 participants)
Number of subjects: 100
Study 28114441 — intervention group
Group type: COMPARATOR
Intervention: Lower-risk group (59 participants)
Number of subjects: 100
Study 28114441 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group comparison (higher-risk vs lower-risk women)
Number of subjects: 100
Study 28114441 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (65 women)
Number of subjects: 100
Study 28114554 — intervention group
Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 879
Study 28114554 — intervention group
Group type: COMPARATOR
Intervention: SIRS
Number of subjects: 879
Study 28114554 — intervention group
Group type: COMPARATOR
Intervention: severe sepsis
Number of subjects: 879
Study 28114604 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod cream, 5% applied topically once per day for 4 consecutive days on specified cycles for 12 weeks, combined with albumin bound paclitaxel, 100 mg/m2 intravenously on days 1, 8, and 15, repeated every 28 days for 12 weeks
Number of subjects: 15
Study 28114884 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vascular endothelial growth factor (VEGF) gene therapy
Number of subjects: 0
Study 28114884 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised longitudinal ultrasound measurements
Number of subjects: 0
Study 28114884 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical markers from maternal blood samples
Number of subjects: 0
Study 28114884 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling for couples with affected pregnancies
Number of subjects: 0
Study 28114884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-banking of maternal blood, urine, amniotic fluid, placenta, umbilical cord blood, and placental bed samples
Number of subjects: 0
Study 28114898 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial empirical antifungal therapy
Number of subjects: 306
Study 28114898 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial pre-emptive antifungal therapy
Number of subjects: 306
Study 28114898 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial targeted antifungal therapy
Number of subjects: 306
Study 28114962 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (Caregivers of cancer Outpatients' Psycho-Education support group therapy), comprising four weekly sessions targeting psychoeducation, skills training, and supportive therapy.
Number of subjects: 0
Study 28114962 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 28114962 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention
Number of subjects: 0
Study 28115071 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS) supported employment for 24 months
Number of subjects: 213
Study 28115490 — intervention group
Group type: EXPERIMENTAL
Intervention: Long noncoding RNAs (lncRNAs) differentially expressed after ischemia in the human heart.
Number of subjects: 0
Study 28115490 — intervention group
Group type: EXPERIMENTAL
Intervention: Long noncoding RNAs (lncRNAs) identified through RNA sequencing.
Number of subjects: 0
Study 28115515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurely born children
Number of subjects: 180
Study 28115515 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls born at term
Number of subjects: 180
Study 28115916 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing in patients with CAD
Number of subjects: 106
Study 28115916 — intervention group
Group type: COMPARATOR
Intervention: Exercise testing in patients without CAD
Number of subjects: 106
Study 28116120 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness-based intervention delivered via Skype group videoconferences
Number of subjects: 60
Study 28116120 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 60
Study 28116164 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise program (intermittent walking to mild-to-moderate claudication pain for three months)
Number of subjects: 48
Study 28116294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine different pulse contour algorithms
Number of subjects: 0
Study 28116335 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudophakic monovision correction (MoG)
Number of subjects: 122
Study 28116335 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal lens implantation (MfG)
Number of subjects: 122
Study 28116595 — intervention group
Group type: EXPERIMENTAL
Intervention: Early fluid administration (total fluid infused in the first 6 hours)
Number of subjects: 2534
Study 28116595 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 2534
Study 28116595 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock status
Number of subjects: 2534
Study 28116595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia as a site of infection
Number of subjects: 2534
Study 28116595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatitis
Number of subjects: 2534
Study 28116595 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute abdomen
Number of subjects: 2534
Study 28117498 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia (measured using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 version)
Number of subjects: 123
Study 28117498 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 123
Study 28117498 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety, type of treatment, back muscle strength, pain severity, and stage of treatment
Number of subjects: 123
Study 28117556 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding for 8 weeks
Number of subjects: 14
Study 28117906 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Cognitive-Affective Therapy (ICAT-BN)
Number of subjects: 80
Study 28117906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy-Enhanced (CBT-E)
Number of subjects: 80
Study 28117906 — intervention group
Group type: COMPARATOR
Intervention: Both ICAT-BN and CBT-E
Number of subjects: 80
Study 28118536 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 17
Study 28118536 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 17
Study 28118536 — intervention group
Group type: COMPARATOR
Intervention: Anakinra vs Canakinumab
Number of subjects: 17
Study 28118823 — intervention group
Group type: EXPERIMENTAL
Intervention: Civic engagement intervention through Change Clubs
Number of subjects: 28
Study 28119279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive nonaction video games (Lumosity)
Number of subjects: 75
Study 28119279 — intervention group
Group type: COMPARATOR
Intervention: The Sims and SimCity (active control)
Number of subjects: 75
Study 28119295 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab (0.1-6.0 mg/kg for Regimen A, 10-18 mg/kg for Regimen B) administered by intravenous infusion, 3 of every 4 weeks for Regimen A or once every 3 weeks for Regimen B.
Number of subjects: 66
Study 28119352 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 97
Study 28119390 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth and home-monitoring systems for asthma management
Number of subjects: 150
Study 28119602 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnuts
Number of subjects: 0
Study 28119602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no walnuts)
Number of subjects: 0
Study 28119625 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of Eosinophil Integrins
Number of subjects: 0
Study 28119763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 827
Study 28119763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 827
Study 28119763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study 28119763 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan (10 mg and 20 mg combined)
Number of subjects: 827
Study 28119821 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase treatment after immunosuppression regimen with cyclosporine and azathioprine
Number of subjects: 6
Study 28119821 — intervention group
Group type: EXPERIMENTAL
Intervention: Laronidase treatment
Number of subjects: 6
Study 28119821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (initial dose: 15 or 20 mg/kg/day) and azathioprine (initial dose: 2.5 or 5 mg/kg/day)
Number of subjects: 6
Study 28119932 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish Diabetes Self-Management Program
Number of subjects: 0
Study 28120036 — intervention group
Group type: EXPERIMENTAL
Intervention: Codrituzumab 2.5 mg/kg qw + Sorafenib 400 mg bid
Number of subjects: 41
Study 28120036 — intervention group
Group type: EXPERIMENTAL
Intervention: Codrituzumab 5 mg/kg qw + Sorafenib 400 mg bid
Number of subjects: 41
Study 28120036 — intervention group
Group type: EXPERIMENTAL
Intervention: Codrituzumab 10 mg/kg qw + Sorafenib 400 mg bid
Number of subjects: 41
Study 28120036 — intervention group
Group type: EXPERIMENTAL
Intervention: Codrituzumab 1600 mg q2w + Sorafenib 400 mg bid
Number of subjects: 41
Study 28120036 — intervention group
Group type: EXPERIMENTAL
Intervention: Codrituzumab 1600 mg qw + Sorafenib 400 mg bid
Number of subjects: 41
Study 28120158 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine, single 266 mg dose (cohort 1)
Number of subjects: 60
Study 28120158 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine, two 266 mg doses (cohorts 2-5)
Number of subjects: 60
Study 28120158 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine, repeated doses at 24, 48, or 72 hours after first dose
Number of subjects: 60
Study 28120158 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for adverse events, neurologic function, cardiac function, and infiltration area abnormalities
Number of subjects: 60
Study 28120370 — intervention group
Group type: EXPERIMENTAL
Intervention: Gesture use as measured by the Communication and Symbolic Behavior Scales-Developmental Profile Caregiver Questionnaire (CQ) and the Autism Diagnostic Observation Schedule (ADOS)
Number of subjects: 197
Study 28120370 — intervention group
Group type: EXPERIMENTAL
Intervention: Gesture use controlling for age
Number of subjects: 197
Study 28120370 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestures at time 1 in a longitudinal subsample of children with ASD
Number of subjects: 197
Study 28120370 — intervention group
Group type: COMPARATOR
Intervention: Gesture use
Number of subjects: 197
Study 28120730 — intervention group
Group type: COMPARATOR
Intervention: Smoke-free legislation in workplaces, tobacco tax increase, mass media campaign (January 2004)
Number of subjects: 2069695
Study 28120730 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension of smoke-free law to hospitality industry, further tax increase, media campaign (July 2008)
Number of subjects: 2069695
Study 28121231 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagreb regimen
Number of subjects: 0